Actively Recruiting
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Led by Northwestern University · Updated on 2026-04-13
60
Participants Needed
1
Research Sites
141 weeks
Total Duration
On this page
Sponsors
N
Northwestern University
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.
CONDITIONS
Official Title
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Over 18 years of age
- Estimated glomerular filtration rate (eGFR) between 25 and 60 ml/min/1.73m2
- On stable doses of diuretics and/or angiotensin converting enzyme inhibitor or angiotensin receptor blocker
- Evidence of subclinical heart failure with preserved ejection fraction shown by specific echocardiography criteria or low peak oxygen consumption on exercise testing
- Left ventricular longitudinal strain less than 18% or left atrial reservoir strain less than 25% on 2D-speckle tracking echocardiography, or lack of increase in these measures during exercise
- Peak VO2 for females 18 mL/kg/min or less and for males 20 mL/kg/min or less on cardiopulmonary exercise testing
You will not qualify if you...
- History or presence of diabetes
- Coronary revascularization within the last 6 months
- Significant valvular heart disease affecting blood flow
- Lung disease requiring home oxygen
- Angina (chest pain)
- Untreated myocardial ischemia
- Systolic blood pressure below 100 or above 180 mmHg
- Pregnancy
- Clinical symptoms of heart failure
- History of systemic diseases causing heart failure with preserved ejection fraction such as amyloidosis or sarcoidosis
- Musculoskeletal or chronic conditions preventing completion of cardiac testing
- Active cancer
- Use of immunosuppressive therapy
- Reduced ejection fraction less than 50% on echocardiogram
- Current treatment with sodium glucose cotransporter 2 inhibitors
- Allergy to sodium glucose cotransporter 2 inhibitors
- Pre-existing liver disease
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels more than three times normal
- History of recurrent urinary tract infections or recent infection within 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Northwestern University
Chicago, Illinois, United States, 60607
Actively Recruiting
Research Team
R
Rupal Mehta, MD
CONTACT
T
Tamara Isakova, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here